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Background: Osteoporosis is one of the commonest bone diseases in which bone fragility is increased. Over
300,000 patients present to hospitals in the UK with fragility fractures each year, with medical and social care costs -
most of which relate to hip fracture care - at around £2 billion. The number of these fractures rises by 2% a year.
The 30 days mortality is 10% and 30% at 1 year. The purpose of this study is to review the current practice
according to NICE and BOA guidelines of secondary prevention of osteoporosis and to suggest changes to these
guidelines.
Methods: Patients over 50 years old admitted as inpatients to our facility with non-neck-of-femur (NOF) fragility
fractures in March and September 2008 were studied. Retrospectively (March), looking for risk factors and if treated
or not, then prospectively (September), after introducing the new trauma admission sheet. Also cross-sectional
study was performed by comparing the services provided for NOF and non-NOF fragility fractures in September.
Two-sample t test is used to compare between percentages.
Results: Twenty-nine percent of fragility fractures are non-NOF fractures with a mean age of 70 years, while the
remaining 71% are NOF fractures with a mean age of 80 years. There is a great difference in the care provided to
these patients: non-NOF fragility fractures got less attention for assessment of osteoporosis (25%) and obtained less
interest in investigations by medical staff (11%) and, finally, less intentions to treat osteoporosis (35%), compared to
NOF fractures in which 35% of cases were assessed, 47% were investigated and 71% were treated for osteoporosis.
Twenty-five percent of NOF fracture patients were found to have previous fragility fractures in the preceding years,
while only 6% were on osteoporosis treatment before the fracture.
Conclusion: Osteoporosis (a new epidemic) is the most common disease of the bone and its incidence is rising
rapidly as the population ages. Though treatable, it is often left untreated. We believe that treating patients with
non-NOF fragility fractures from osteoporosis before proceeding to NOF fractures would improve their quality of life
and reduce the burden on hospital services and funding.
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Osteoporosis is the most common disease of bone (new
epidemic) [1]. It is a state in which the bone is fully min-
eralized but its structure is abnormally porous and its
strength is less than normal for a person of that age and
sex, and this is accompanied by increased fragility [2]. It is
estimated that 1.2 million women in the United Kingdom
have osteoporosis (T-score <2.5) [3]. Over 300,000 pa-
tients present to hospitals in the UK with fragility frac-
tures each year, with medical and social care costs - most
of which relate to hip fracture care - at around £2 billion
[1]. In 2007, 70,000 people over 60 years of age suffered a
hip fracture; the number rises by 2% a year. Current pro-
jections suggest that, in the UK, hip fracture incidence will
rise to 91,500 in 2015 and 101,000 in 2020. Currently, the
annual UK healthcare costs alone (at £7000–£12 000 per
patient fracture), are £1.8 billion. The 30 days mortality is
10% and 30% at 1 year [1]. In Australia, currently 2.2 mil-
lion Australians have osteoporosis and this is expected to
increase to 3 million by 2021 [4,5].
Despite the known impact of fragility fractures, osteo-
porosis still remains unrecognised and untreated in over
50% of patients who present with fragility fractures.
Orthopaedic surgeons are often the first to encounter
these patients who present with fragility fractures [6].
UK standards
National Institute for Health and Clinical Excellence
(NICE) published the guidelines and recommendations
(issued 2008, last update 2011): use of bisphosphonates,
selective oestrogen receptor modulators (raloxifene) and/
or parathyroid hormone (teriparatide) to reduce the risk
of further osteoporosis-related fractures in women who
have gone through the menopause and who have already
had an osteoporosis-related fracture [3]. Treatment is of-
fered to prevent further fractures that will depend on the
patient's age, her bone density and how many risk fac-
tors for fracture she has [3]. Alendronate is recom-
mended as a possible treatment to prevent bone loss
in postmenopausal women who have already had a frac-
ture and have had osteoporosis diagnosed. If a woman
cannot take alendronate, risedronate and etidronate are
recommended under certain circumstances as possible
alternative treatments to prevent further fractures. If a
woman cannot take alendronate or either risedronate











32 33/83 (40%) 50/83 (60%)are recommended under certain circumstances as possible
alternative treatments to prevent further fractures. If a
woman cannot take alendronate or either risedronate or
etidronate, or strontium ranelate, teriparatide is recom-
mended under certain circumstances as a possible alterna-
tive treatment to prevent further fractures. Teriparatide is
also recommended as a possible alternative treatment for
a woman who has another fracture when she has been
taking alendronate, risedronate or etidronate for 1 year
and her bone density has fallen [3]. The guidance says that
women who are 75 or over may not need a bone scan to
diagnose their osteoporosis [3]. Sustaining a fragility frac-
ture at least doubles the risk of future fractures; that risk
remains for 10 years and is greatest in the first year after
the original fragility fracture [7].
The British Orthopaedic Association (BOA) published
the blue book (September 2003, updated 2007) - The
care of patients with fragility fractures - and suggests the
following components to prevention [1]: (a) assessment
and treatment of osteoporosis, (b) prevention of falls, (c)
prevention of hip fractures by use of hip protectors, and
(d) ‘A Fracture Liaison Service’, delivered by a nurse spe-
cialist, which is a proven approach.
The purpose of this study is to assess the current prac-
tice according to NICE and BOA guidelines of the sec-
ondary prevention of osteoporosis and to suggest
changes to these guidelines.
Methods
Our research is a cohort study conducted in Morriston
Hospital in Swansea (from May to October 2008), up-
dated with literature review in 2013. Ethical approval
was not required for this study.
All patients over 50 years old admitted (in our institu-
tion: Morriston Hospital, Swansea, UK) with non-neck-
of-femur fracture, in March and September 2008, were
identified and studied. Retrospectively, March admissions
were checked for risk factors and noted if appropriatelyTable 3 Male/female ratio and percentage of female to


























Not assessed 7/20 (35) 12/48 (25)
Values are presented as number/total (percentage).
Table 4 Percentages of fragility fractures to all fractures


















Male 5/10 (50) 7/15 (47) 17/19 (89)
Female 18/22 (82) 13/18 (72) 31/31 (100)
Values are presented as number/total (percentage).
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screening pro forma, September admissions were studied
in the same way. Cross-sectional study is used to compare
the neck-of-femur (NOF) to non-NOF fragility fractures
(in September).
This was done by checking the following: (1) patients'
score (for osteoporosis risk), (2) appropriate treatment
initiated in the hospital and (3) patients who continued
treatment after discharge.
The following are the inclusion criteria:
1. Patients presenting with non-neck-of-femur fragility
fractures
2. Over 50 years of age
3. Admitted to hospital as inpatient in March and
September 2008
Out of 89 patients over 50 years old, with fractures
admitted from Accident and Emergency (A & E) in
September 2008, 83 files of patients were studied. Fifty
patients were admitted with NOF fractures (60%), in
which all proximal femoral fractures are included in this
category, while 33 patients had non-NOF fragility frac-
tures (40%).
In March 2008, there were 60 patients admitted with
fractures mostly from A & E and few from fracture clinic
with non-NOF fragility fractures. Randomly, 37 cases
were studied, and 5 of these were excluded due to in-
complete information.
We aimed to assess the current practice with regards
to the guidelines of secondary prevention of osteoporosis
for hospital admissions. The statistical test used forTable 5 Site of fracture (non-NOF fragility fractures)
March September Total
Upper limb 15/32 (47) 14/33 (42) 29/65 (44.6)
Lower limb (non-NOF,
non-pelvis)
12/32 (37.5) 18/33 (55) 30/65 (46.2)
Pelvis 3/32 (9) 1/33 (3) 4/65 (6.2)
Vertebrae 2/32 (6.5) 0/33 (0) 2/65 (3)
Values are presented as number/total (percentage).comparison is the two-sample t test (between percents)
and the p value calculated is a two-tailed probability.
Results
The results are presented in Tables 1,2,3,4,5,6,7,8,9,10,11.
While the majority of non-NOF fractures are females
(65%), about one third of fragility fractures over 50 years
old are males (Tables 3,4,11).
Twenty-five percent of patients with NOF fragility
fractures had prior non-NOF fragility fractures. Only 6%
of the NOF fragility fracture patients were on osteopor-
osis treatment before the new fracture (Tables 6 and 9).
The introduction of the new trauma admission sheet
in our institution in August 2008 showed some improve-
ment in the care provided for non-NOF fragility frac-
tures (Table 9).
There is a great difference in the care provided to the
patients with fragility fractures between non-NOF and
NOF fractures. Unfortunately, non-NOF fractures got
less attention for assessment of osteoporosis (25%) com-
pared to 35% for NOF, less interest in investigations
(11%) compared to 47% for NOF and finally, less
intention to treat (35%) compared to 71% for NOF
(Table 11).
Discussion
Based on the above results, the following points are raised:
 NICE guidelines did not include about one third of
the cases which comprises the male ratio in fragility
fractures over 50 years old. No recommendation
was made for the length of osteoporosis treatment.
 Morbidity, mortality and loss of independence after
major fragility fracture are greater in men than
women [8].
 The introduction of the new trauma admission sheet
in our institution in August 2008 showed some
improvement in the care provided for non-NOFTable 7 Osteoporosis assessment (compliance by staff) in
September (via our new purple admission sheet)
September (for all fractures
NOF and non-NOF)
Patients assessed for osteoporosis 22/83 (26.5)
























Both 2 4 22
Total 5 7 34
Table 8 Percentage of DEXA requested for patients












75 with fragility fractures
2/12 (16.5) 1/9 (11) 7/15 (47)
Values are presented as number/total (percentage). DEXA, dual-energy
X-ray absorptiometry.
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remarkable improvement regarding history taking,
proper description of the mechanism of injury,
previous fragility fractures and osteoporosis
assessment. On the other hand, there was no
significant difference in the treatment provided for
osteoporosis of these fragility fractures (22% in
March and 35% in September).
 There is a great difference in the care provided for
patients with fragility fractures between non-NOF
and NOF fractures. Unfortunately, non-NOF
fractures have got less attention for assessment of
osteoporosis (i.e. 25% - compared to 35% for NOF -
p value 0.42), less interest in investigations
(i.e. 11% - compared to 47% for NOF - p value
0.006) and finally less intentions to treat (i.e. 35% -
compared to 71% for NOF - p value 0.007) (the
statistical test used for comparison is: 2 sample t test
between percents). The p value calculated is two-
tailed probability (Table 11).
 While 25% of NOF fragility fracture patients had
previous non-NOF fragility fractures, only 6% of the
NOF fractures patients were on osteoporosis
treatment (Table 9).
 Non-NOF fractures are about 29% (of the total
number of fragility fractures studied in our inclusion
criteria) with a mean age of 70 years, compared to
NOF fractures, which are 71% with a mean age of
80 years. The majority of non-NOF fractures are





ready on treatment 1
n admission 1
arted later in hospital 3 (average starting is 4 days
after admission)
treatment (treatment missed) 18
tal 23/23
eated patients (n (%)) 5/23 (22) NICE guidelines did not include the non-NOF
fragility fracture patients as crucial targets for
osteoporosis assessment and treatment.
 This research is limited to the inpatient admissions
as better documentation and care would be
expected. On the other hand, the vast majority of
patients with non-neck-of-femur fragility fractures
are seen in fracture clinics and to a less extent in GP
practice.
 In our study we found that the osteoporosis targets
are clearly not being reached. Risk stratification is
not being undertaken and cost-effective secondary
prevention is not being utilised effectively. Below
target results were also found in other studies and
researches [9].
Recommendations
Based on the above findings, we would like to suggest
the following recommendations:




7/2(a) Education for new juniors at induction
(b) Highlighting for seniors
(c) Introduction of clinical pathway including
assessment sheet would be beneficial if well
designed







0 24 (average starting is 2.7 days after admission)
13 14 (probably included in the study before
orthogeriatrics commence treatment)
/20 48/48
0 (35) 34/48 (71)
Table 11 Comparison between non-NOF fragility fractures





Mean age 70 80




Cases (%) 40 60
Fragility fractures (n (%)) 20/68 (29) 48/68 (71)
Patients assessed for osteoporosis
(by completion of the new admission
sheet) (n (%))
5/20 (25) 17/48 (35)
Requested DEXA (%) 11 47
Treated patients (n (%)) 7/20 (35) 34/48 (71)
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hospital or GP practice for recruiting suitable
patients and commencing osteoporosis
treatment
(f ) Continuous practice monitoring and regular
auditing2. New recommendations:(a) Inclusion of men in the guidelines of assessment
and treatment of osteoporosis
(b) Treating non-NOF fragility fractures from
osteoporosis before proceeding to NOF fractures3. Considering the recruitment of nurse specialists into
fracture clinics for A Fracture Liaison Service, which
is a proven approach to the identification,
assessment and treatment of fracture risk [1,10]
4. Develop liaisons with interested general practitioners,
the nearest osteoporosis lead physician and falls
service
5. Consider arranging sessions for these patients in
fracture clinics for advice and initiation of
osteoporosis treatment (by the specialist nurse) [1]
6. Coordination and teamwork between orthopaedics
and orthogeriatrics
Conclusions
Osteoporosis (a new epidemic) is the most common dis-
ease of the bone and its incidence is rising rapidly as the
population ages. Though treatable, it is often left un-
treated. Non-NOF fragility fractures got less attention
for investigation and treatment of osteoporosis com-
pared to NOF fragility fractures.
The guidelines for assessment and treatment of osteo-
porosis should include non-NOF fragility fractures as
crucial targets before they proceed to NOF fractures.
These measures would improve the quality of life forpatients and would reduce the medical and social care
costs by decreasing the number of NOF fragility fracture
cases.
Men represent about one third of fragility fracture pa-
tients over 50 years old. Also, Morbidity, mortality and
loss of independence after major fragility fracture are
greater in men than women. We recommend the inclu-
sion of men in the guidelines for assessment and treat-
ment of osteoporosis.
Better coordinated services (offering early diagnosis
and bone protection, optimal fracture care and second-
ary prevention) would improve quality of life for patients
and reduce the burden on hospital services and govern-
ment funding especially by treating non-NOF fragility frac-
tures from osteoporosis before proceeding to NOF fractures.
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